Introduction
Drug safety, also known as pharmacovigilance, is defined by the World Health Organization (WHO) as "the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other possible drug-related problems" (WHO 2002) . How to detect signal of adverse drug reactions (ADRs) has become one important issue of drug safety. In 2000, ADR was defined comprehensively by Edwards and Aronson (Edwards and Aronson 2000) as: "an appreciably harmful or unpleasant reaction, resulting from an intervention related to the use of a medicinal product, which predicts hazard from future administration and warrants prevention or specific treatment, or alteration of the dosage regimen, or withdrawal of the product". In the United States, it is estimated that approximately 2 million patients are affected each year by ADRs (Liu and Chen 2013) and associated cost is up to about 75 billion dollars annually (Sarker et al. 2015) . Therefore, how to effectively and efficiently detect ADR signals is of paramount importance for drug manufacturers, government agencies, as well as health consumers.
Currently, there are two major pharmacovigilance processes: pre-marketing clinical trials and post-marketing surveillance. The pre-marketing process is often too constrained in terms of sample size, cohort biases, time spans, and financial limit to possibly identify all potential adverse reactions that may occur after the drug is released into the market (van der Heijden et al. 2002) . Therefore, drug safety depends heavily on post-marketing surveillance to detect latent adverse reactions. Several traditional data sources are often mined to serve this purpose, such as spontaneous reporting systems, electronic health records, and biomedical literature. However, these sources bare their own limitations that to some extent hinder effective and confident drug safety signal detection. For instance, spontaneous reporting systems have extremely high underreporting ratio systems (van der Heijden et al. 2002) , electronic health records are not accessible to everyone due to privacy issue, formally-written literature has long publishing cycle, etc.
Therefore, it is urgent to find alternative data sources to supplement drug safety surveillance.
Nowadays, the advancement of Internet breeds a lot of online health communities (OHCs) such as MedHelp, WebMD, PatientsLikeMe, DailyStrength, etc. A recent survey by Pew Internet & American Life Project showed that 72% of internet users said they went online for health information in 2012, 13% of which said they began their information seeking by visiting a site that specializes in health information, like WebMD (Fox and Duggan 2013) . We can imagine that uncountable health consumers and professionals go to those OHCs frequently to either seek or offer healthcare information. Frequent visits on OHCs would inevitably generate a huge volume of health-related contents that might be even more informative than some administrative databases. In the recent years, there are an increasing number of studies dedicated to ADR detection using timely and publicly-available health consumer-contributed content from such platform and promising results have been shown. For example, using DailyStrength as the source of user comments, Leaman et al. extracted adverse reactions by matching the terms in user comments with a lexicon (Leaman et al. 2010 AZDrugMiner system -based on statistical learning to extract adverse drug reactions in patient discussions (Liu and Chen 2013) . Yang et al. showed ADRs signals that were alerted by US Food and Drug Administration could be identified by mining OHC forums (Yang et al. 2012a; Yang et al. 2014; Yang et al. 2012b; Yang and Yang 2015) .
The number of studies that utilized OHC data is still limited, and more efforts need to be made.
A recent survey on pharmacovigilance showed that as many as 73% papers published within the last two years used annotated data that requires a lot of expert efforts (Sarker et al. 2015) . Also, most of those papers used content analysis techniques, ignoring the fact that an OHC is also a heterogeneous network. In this work, we propose an annotation-free technique for ADR detection: mining the structural information of weighted heterogeneous healthcare networks.
Methods

Heterogeneous Healthcare Network Definition
A heterogeneous network is defined as a graph G = ( , ℒ) consisting of nodes joined by links, where N = {n 1 , n 2 , … , n g }, L = {l 1 , l 2 , … , l L } and l i can be directional or non-directional. In the graph G, each node n i ∈ belongs to one particular type from , each link l i ∈ ℒ belongs to one particular relation from ℛ, and the number of the types of nodes We define a network model = ( , ℛ) as a compressed representation for a heterogeneous network = ( , ℒ), which is a directional or non-directional graph consisting of node types , with links as relations from ℛ. Figure 1 succinctly presents a non-directional network model of a heterogeneous healthcare network. As we can see, the network includes four types of nodes, propose to analyze a non-directional heterogeneous healthcare network that contains above 4 types of nodes joined together by their co-occurrence in an analysis unit. are often used in association rule mining, one of the most important and well researched techniques of data mining, to measure the interestingness of an association. Given a link between nodes and , LV and LT are defined respectively as:
( ) and ( ) denote node frequency (number of threads that contain the node) of node and respectively, and is the total number of threads in the dataset.
After adding weight to the network, we propose to use Weighted Path Count (WPS) to quantify the extracted topological features. Given a − ℎ − , the WPC is defined as:
, where denotes a specific path, is the length of , and +1 are two directly connected nodes following , and ( , +1 ) is weight of the corresponding link connecting node and +1 . Take the network in Figure 2 . In this way, we can tell that for 1 and 3 , path − − − has stronger association than − − − .
ADR Detection Model
We model ADR detection as a binary classification problem. Concretely, given a drug-ADR pair,
we use a classification model to label them as either "1" (drug causes the ADR) or "0" (drug does not cause the ADR) based on their quantified topological features extracted from the namely Blurred Vision, Cancer, Depression, Diarrhea, Heart Disease, Hypertension, Kidney Disease, Skin Discoloration, Stroke, and Suicide.
Network Construction
As mentioned earlier, we focus on four types of nodes, namely R, A, D, and U, and external lexicons are used to extract them. For R, we use the 20 drugs collected from MedHelp. For A, we focus the 10 ADRs mentioned in gold standard section, and use Consumer Health Vocabulary (CHV) Wiki 4 to build our ADR lexicon. CHV reflects the difference between consumers and professionals in expressing health concepts and helps to bridge this vocabulary gap. Therefore, high quality CHV is able to help with capturing more consumers' expressions and better extracting ADR terms. Some studies are dedicated to expanding CHV by using social media data (Jiang and Yang 2013; Jiang and Yang 2015) . For D, we search for diseases that are treated by each of the 20 drugs in SIDER database 5 to construct our disease lexicon. SIDER contains information such as adverse drug reactions and diseases on marketed medicines, and the information is extracted from public documents and package inserts (Kuhn et al. 2010) . At last, there are 205 diseases in total, such as Bipolar Disorder, Hyperactivity Disorder, Hypercholesterolaemia, and so on. For U, we extract all user names from each thread. The dataset is de-identified before conducting the experiment. For links, we treat our network as nondirectional, and two nodes are linked together if they co-occur in the same thread.
Experiment Settings
In order to exclude the nodes and links that appear in the heterogeneous healthcare network rarely, we only retain the nodes and links with frequency larger than 15. After filtering, there are 509 nodes and 4344 links in our final network. For each drug-ADR pair, we use the 17 paths as their topological features. Then we weight the network with LF, LV, and LT respectively and quantify the extracted features using WPC. We found that our dataset is highly imbalanced, and the ratio of positive (labeled as 1) and negative (labeled as 0) drug-ADR pairs is approximately 1:14. Therefore, we performed undersampling to build a new dataset with an equal sized set of positive and negative pairs. The experiment process is summarized as follows: (1) Undersampling: Given the positive drug-ADR pairs, randomly select an equal sized set of negative pairs to form a new dataset; (2) (1) to (3) 5,000 times.
Evaluation
To evaluate the effectiveness of the proposed approaches, we set up a comparison between weighted and non-weighted heterogeneous healthcare networks. Specifically, we constructed a non-weighted heterogeneous network, extracted all the 17 − ℎ − and used path count to quantify them. Then we conducted the same 4-step experiment as shown in previous section.
We use both F1 score and area under the ROC curve (AUC) to evaluate the performance. Here the F1 and AUC scores are the average value of the 5,000 repeated experiments. Figure 3 and Figure 4 show the performance comparisons of different network weighting schemas using different classifiers in terms of F1 score and AUC score respectively. We can observe that, in all scenarios, Hete_LV and Hete_LT outperform non-weighted network and network weighted by link frequency except AUC score using Naïve Bayes as classifier. We also conducted ANOVA analysis to see, for each classifier, if there is any significant difference between different network weighting schemas. Both Welch procedure (p = .000) and
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Brown-Forsythe procedure (p = .000) showed that a statistically significant difference exists in terms of both F1 score and AUC no matter which classifier is used. Furthermore, for both F1 and AUC scores under all three classifiers, Games-Howell post-hoc tests demonstrated that (1) Hete_LV is statistically significantly higher than all other three network weighting schemas (p = .000 for all comparisons) except its AUC score is significantly lower than Hete_Non-weighted (p = .000) and Hete_LT (p = .000) when Naïve Bayes is used; (2) Hete_LT is significantly higher than both Hete-Non-weighted and Hete_LF (p = .000 for all comparisons) except its AUC score is significantly lower than Hete_Non-weighted (p = .000) when NB is used. Last but not least, ANOVA analysis under network weighting schema Hete_LV showed that (1) for F1 score, NB is significantly higher than both LR (p = .000) and SVM (p = .000), and SVM is significantly higher than LR (p = .000); (2) for AUC score, SVM is significantly higher than both LR (p = .000) and NB (p = .000), and LR is significantly higher than NB (p = .000).
The results demonstrate that (1) the performance of different classifiers varies under different evaluation scenarios, and (2) leverage-and lift-weighted heterogeneous healthcare networks are generally more effective in ADR detection than non-weighted and frequency-weighted heterogeneous network. Link frequency is proportional to its support value ( ( ) = ( ) ), which is not enough to represent the information carried by links. For example, considering a link R -A, its support value could be very small, but it does not mean that this link is trivial, because this ADR could be one of the rare ADRs that would be caused by the drug.
One limitation of support lies in the fact that it would work well when the ADR of the drug appear frequently in the dataset. However, health consumers discuss diverse aspects of drugs in online forum, such as drug dosage, drug prescription, concomitant use of different drugs, and so forth. It is very likely that threads that are related to the specific ADR are only a small portion of the total threads, especially for those rare ADRs. Leverage and lift could be used to address this problem because they incorporate the support of the ADR in the dataset. Both leverage and lift measure the strength of a link not only by looking at its support but also the correlation between the two nodes. Leverage measures the difference between the proportion of threads containing both nodes above those expected if the two nodes were independent of each other whereas lift calculate the ratio of these two. Therefore, both leverage-and lift-weighted heterogeneous network perform better than frequency-weighted one. 
Conclusion
The development of Health 2.0 technologies leads the booming of OHCs such as MedHelp, WebMD and so on. Such platforms are not only empowering individuals to play a substantial role in their own health, but also generating informative data that can be used to provide automated insights and discovery. Since ADRs represent a serious health problem all over the world, how to detect ADR signals effectively and efficiently has been of great medical significance. In this study, we proposed to harness OHC data for ADR signal detection. We used
MedHelp as our source to collect consumer-contributed contents based on which a weighted heterogeneous healthcare network was constructed. Then we extracted topological features from the network, quantified them using different weighting schemas, and used supervised learning techniques for ADR detection. The experiment results showed that the proposed weighted heterogeneous healthcare network substantially outperformed the non-weighted counterparts. In the future, this work could be extended in several directions: (1) more types of nodes could be added into the heterogeneous healthcare network such as diagnostics, treatments, etc.; (2) various co-occurrence levels can be considered, such as post and sentence; (3) asymmetric paths could also be considered as topological features; (4) other than using undersampling to build a balanced dataset, more machine learning techniques could be considered such as oversampling, cost-sensitive learning, ensemble learning, etc.
